Evidence map›Paper›PMID 40864796›Full record

ArticleCurrent issues in molecular biology2025

Molecular Insights into Tumor Immunogenicity.

Irini Doytchinova, Stanislav Sotirov, Ivan Dimitrov

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Irini DoytchinovaDrug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, Dunav St. 2, 1000 Sofia, Bulgaria.ORCID 0000-0002-1469-1768
Stanislav SotirovDrug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, Dunav St. 2, 1000 Sofia, Bulgaria.
Ivan DimitrovDrug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, Dunav St. 2, 1000 Sofia, Bulgaria.ORCID 0000-0003-4838-312X

Funding

European Union NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

Tumor immunogenicity depends on the ability of peptides to form stable and specific interactions with both HLA molecules and T-cell receptors (TCRs). While HLA binding is essential, not all HLA-binding peptides elicit T-cell responses. This study investigates the molecular features distinguishing immunogenic T-cell epitopes from non-immunogenic HLA binders. Two datasets of nonamer peptides-38 T-cell epitopes and 144 non-epitopes-were compiled and analyzed using sequence logo models and molecular dynamics (MD) simulations of TCR-peptide-HLA complexes. A comparative logo analysis revealed strong amino acid preferences at central positions (p4-p8) in T-cell epitopes and absences in non-epitopes. A representative epitope-non-epitope pair was selected for structural modeling and 100 ns MD simulations. The T-cell epitope formed a more stable complex with the TCR and exhibited greater flexibility, supporting an induced-fit recognition mechanism. It also established a broader and longer-lasting network of hydrogen bonds and π interactions across the residues at positions p4-p8. In contrast, the non-epitope engaged TCR at only two positions. These findings highlight the critical role of the peptide's central region in TCR engagement and provide structural insights useful for neoantigen prediction, vaccine design, and TCR-based immunotherapies.

Indexed as

HLA class I bindersimmunogenicitymolecular dynamics simulationsneoantigen predictionT-cell epitopesTCR-based immunotherapiesvaccine design

Identifiers

PMID40864796
PMCPMC12384583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.